Semaglutide, the GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, reduced alcohol consumption by 40% and severe craving episodes by 54% in patients with alcohol use disorder (AUD) in a double-blind randomized crossover trial — revealing a potentially transformative off-target effect of this drug class on brain reward circuitry.

GLP-1 Receptors in the Reward System

GLP-1 receptors are expressed not only in the pancreas and gut — where their insulin-stimulating and appetite-suppressing effects are well characterized — but throughout the central nervous system, including the nucleus accumbens, ventral tegmental area, and prefrontal cortex. These regions collectively constitute the mesolimbic dopamine reward pathway, the neural substrate of addiction to alcohol, opioids, and other substances.

Animal studies demonstrating that GLP-1 receptor activation reduces alcohol consumption in rodent models date to 2015. Epidemiological analyses of large GLP-1 prescribing databases subsequently found lower rates of alcohol-related hospitalizations among semaglutide users compared to matched controls — setting the stage for this controlled trial.

Trial Design

The REWARDS trial enrolled 127 adults meeting DSM-5 criteria for moderate-to-severe AUD (≥4 heavy drinking days per week at baseline). In the crossover design, participants received 16 weeks of once-weekly subcutaneous semaglutide (escalating to 1.0 mg) and 16 weeks of matching placebo, with an 8-week washout between periods.

Results

During semaglutide treatment, participants consumed a mean of 40% fewer standard drinks per week compared to placebo periods (11.4 vs 19.0 drinks/week). Heavy drinking days (≥4 drinks for women, ≥5 for men) were reduced by 47%. Severe craving episodes — assessed daily via ecological momentary assessment — were reduced by 54%. Liver function tests (AST, ALT, GGT) improved significantly during semaglutide treatment.

The effect was larger in participants with higher baseline craving scores and in those with the Taq1A1 allele of the dopamine D2 receptor gene — a finding consistent with semaglutide acting on dopaminergic reward signaling.

Mechanism

Functional MRI sub-studies showed that semaglutide blunted BOLD signal responses in the nucleus accumbens during alcohol cue exposure, suggesting direct modulation of cue-reactivity in the reward system. The effect was not fully explained by weight loss (average 4.2 kg during semaglutide period) or reduced caloric intake.

Clinical Implications

Only three FDA-approved pharmacotherapies exist for AUD — naltrexone, acamprosate, and disulfiram — and all have significant limitations including poor adherence, contraindications, and modest efficacy. A Phase 3 trial of semaglutide specifically for AUD has been initiated with results expected in 2027.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.